Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.

Jeremy P. Berman, Jonathan L. Halperin

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Patients with atrial fibrillation (AF) face an elevated risk of stroke compared with patients who have normal sinus rhythm. Warfarin, an oral vitamin K antagonist, is a highly effective therapeutic agent to reduce stroke risk in patients with AF; however, use of warfarin is complicated by variable patient dose response due to genetic factors and multiple food-drug and drug-drug interactions. Novel oral anticoagulants appear to be a safe, effective alternative to warfarin therapy without the need for routine coagulation monitoring. Dabigatran, a direct thrombin inhibitor, has been commercially available since 2010 for prevention of stroke in patients with nonvalvular AF. More recently, the US Food and Drug Administration (FDA) approved 2 oral activated factor X inhibitors, rivaroxaban and apixaban, for stroke prevention in patients with AF based on clinical trial evidence of their safety and efficacy. In this article, we provide an overview of the 3 novel oral anticoagulants for treating patients with AF and discuss the latest findings from subgroup analyses.

Original languageEnglish (US)
Pages (from-to)37-48
Number of pages12
JournalUnknown Journal
Issue number1
StatePublished - Feb 2013

Bibliographical note

Funding Information:
The manuscript was prepared by the authors. The authors would like to acknowledge Geraint Owens, who provided editorial assistance with funding from Bayer HealthCare Pharmaceuticals and Janssen Pharmaceuticals, Inc.


Dive into the research topics of 'Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.'. Together they form a unique fingerprint.

Cite this